

- Biological basics (*continued*)
 - cell nutrients, 46-52
 - growth media, 52
 - macronutrients, 48, 49-50
 - micronutrients, 48, 50-51
 - microbial diversity, 11-12
 - aerobic organisms, 11-12
 - anaerobic organisms, 11-12
 - bacillus, 12
 - coccus, 12
 - extremophiles, 12
 - facultative organisms, 12, 53
 - mesophiles, 11
 - psychrophiles, 11
 - spirillum, 12
 - thermophiles, 11
 - procaryotes, 15-19
 - archaeobacteria, 17-19
 - eubacteria, 15-17
 - viruses, 14-15
- Biological engineering, 2
- Biological films, 266-68
 - defined, 266
 - schematic representation of, 268
 - thickness of, 267-68
- Biological oxygen demand (BOD), 489-90
 - BOD removal, 493, 503
- Biological waste treatment, 488-508
 - advanced waste-water treatment systems, 501-8
 - defined, 489
 - overview, 488-91
 - primary treatment, 491
 - processes, 491-501
 - activated-sludge processes, 491-95
 - anaerobic digesters, 499-501
 - oxidation ponds, 499
 - rotating biological contactors (RBC), 498-99
 - trickling biological filters, 496-98
 - secondary treatment, 491
 - sludge, 491
 - tertiary treatment, 491
 - waste-water carbon content, 489-90
 - waste water, conversion to useful products, 506-8
- Bioluminescence, 128
- Biomedical engineering, 2
- Biomolecular engineering, 2
- Biopharmaceutical products, 423
- Biopolymers, 25-26
- Bioprocess engineer, 1-10
 - bioprocess engineering, 2
 - bioprocess regulatory constraints, 8-10
 - biotechnology, 2
 - penicillin, 3-8
 - research approach, 3
- Bioprocess engineering, defined, 2
- Bioprocess engineering medical applications, 463-74
 - bioreactors, 471-72
 - extracorporeal artificial liver, 472
 - stem cells and hematopoiesis, 471-72
 - gene therapy using viral vectors, 467-71
 - retro virus, mass production of, 470-71
 - viral infection models, 467-70
 - tissue engineering, 463-66
 - chondrocyte culture for cartilage replacement, 465-66
 - commercial tissue culture processes, 465-66
 - compared to protein production from mammalian cells, 464
 - defined, 463-64
 - tissue-engineered skin replacements, 465
- Bioprocess regulatory constraints:
 - FDA drug approval process, 9
 - good laboratory practices (GLP), 9
 - good manufacturing practice (GMP), 9
 - guideline updates, 9-10
 - standard operating procedures (SOPs), 9
- Bioreactors, 285-328, 471-72
 - for animal cell cultures, 396-400
 - cleaning, 291
 - in continuous cultivation, 189-99
 - cultivation methods, 387-96
 - data logging, 311
 - extracorporeal artificial liver, 472
 - height-to-diameter ratio, 297
 - immobilized cell systems, 263-75, 285
 - instrumentation for measurements of active fermentation, 307-11
 - mixed cultures, 487-508
 - for plant cell cultures, 411-17
 - for plant cells, 407
 - scale-up, 286-306
 - reactor types, 286-92
 - stem cells and hematopoiesis, 471-72
 - and sterility, 291
 - sterilization, 291, 314-23
 - stirred-tank reactor, 286, 288
 - suspension cultures, 408-9, 410, 411-13
- Biosynthesis, 145-48
- Biotin, 51